Zealand Pharma shares fall 20% on survodutide tolerability data

The wire

1. 01Zealand Pharma shares dropped more than 20% in early Monday trading after trial data showed survodutide had worse side effects and higher patient dropout rates than rival obesity drugs.
2. 02Tolerability and discontinuation rates are the practical dividing line between incretin candidates for prescribers and operators managing dose escalation and patient retention.
3. 03The report gives no specific adverse-event or dropout figures, so the magnitude of the gap versus competing agents remains unclear pending full data disclosure.

From the source

Zealand Pharma shares drop 20% as obesity drug side effects raise concerns

Zealand Pharma's (ZELA.COA) shares fell more than 20% in early trade on Monday after trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than rival treatments.